Indian generic firms woes benefit others

|By:, SA News Editor

Amidst the flurry of regulatory warnings to Indian generic drug manufacturers, other firms will quickly step in to satisfy demand. Those who can demonstrate a strong emphasis on quality will have an edge.

India's Ranbaxy Labs, the largest manufacturer by sales, had its products banned by the FDA in January because of repeated quality problems.

(ACT) (TEVA) (MYL) (CVS) (WAG)